Myriad Genetics, Inc. MYGN
Set alert
At close · Nov 2
After hours · Nov 2, 4:55 PM ET
- YTD
- -4.88%
- 1 year
- -27.24%
- Open
- 6.36
- Prev close
- 6.35
- Mkt cap
- 559.55M
- Vol
- 1.35M
- Avg vol
- 2.42M
- EPS
- -1.18
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 5.82
- High
- 6.46
- Forward P/E
- 71.53
- Beta
- 1.89
- Short ratio
- 4.83
- Inst. own
- 103.89%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 13.32
- 200-d avg
- 21.11
- 1y target
- 19.41
News
8 hours ago globenewswire.com
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
SALT LAKE CITY, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces that Myriad management will…
1 week ago globenewswire.com
Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
SALT LAKE CITY, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces new data from the ongoing…
1 week ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers SCWorx (NASDAQ:WORX) stock moved upwards by 42.9% to $3.83 during Tuesday's regular session. Myriad Genetics (NASDAQ:MYGN) shares moved upwards by 36.85% to $5.76. The company's market cap…
1 week ago benzinga.com
Myriad Genetics Offloads Struggling Prenatal Unit for $210 Million to Labcorp
Labcorp Holdings Inc. (NYSE:LH) has agreed to acquire the prenatal health testing business of Myriad Genetics Inc. (NASDAQ:MYGN) in an all-cash transaction valued at $210 million, plus the value of…
1 week ago benzinga.com
Myriad Genetics Offloads Struggling Prenatal Unit for $210 Million to Labcorp
Labcorp will purchase Myriad Genetics' prenatal testing business for $210 million in cash, projecting $160 million in year-one revenue.
1 week ago benzinga.com
Nasdaq Rises Over 100 Points; 3M Earnings Top Views
U.S. stocks rose Tuesday, led by the Dow, as 3M beat estimates. Braze and Myriad surged, while GM fell; oil and silver gained.
1 week ago benzinga.com
Hasbro Posts Upbeat Q3 Earnings, Joins Myriad Genetics, Equifax And Other Big Stocks Moving Higher On Tuesday
U.S. stocks mixed; Dow rose 400 points. Hasbro surged on strong earnings and outlook, while Braze, Myriad Genetics and others gained.
-
1 week ago benzinga.com
Myriad Genetics To Sell Its Prenatal Health Testing Business, Including Prequel, Foresight, SneakPeek And FirstGene Tests, To Labcorp For $210M In Cash Plus Inventory Value
When complete, the transaction is expected to provide more patients and physicians with expanded access to Labcorp’s comprehensive, high-quality laboratory services, convenient patient service center…
1 week ago globenewswire.com
Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
SALT LAKE CITY and BURLINGTON, N.C., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, and Labcorp (NYSE: LH), a…
2 weeks ago globenewswire.com
Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026
SALT LAKE CITY, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its third quarter 2026 earnings…
-
2 weeks ago benzinga.com
TD Cowen Maintains Hold on Myriad Genetics, Raises Price Target to $4.5
TD Cowen analyst Kyle Boucher maintains Myriad Genetics (NASDAQ:MYGN) with a Hold and raises the price target from $4 to $4.5.
3 weeks ago defenseworld.net
ADMA Biologics (NASDAQ:ADMA) & Myriad Genetics (NASDAQ:MYGN) Critical Analysis
Myriad Genetics (NASDAQ: MYGN - Get Free Report) and ADMA Biologics (NASDAQ: ADMA - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two…
-
3 weeks ago benzinga.com
SOPHiA GENETICS, Myriad Genetics Collaborate To Advance New Prostate Cancer-specific Genomic Instability Score Technology
SOPHiA GENETICS (NASDAQ:SOPH) and Myriad Genetics, Inc., (NASDAQ: MYGN) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support…
3 weeks ago prnewswire.com
SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
BOSTON, Oct. 8, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) and Myriad Genetics, Inc., (NASDAQ: MYGN) today announce a collaboration to advance new prostate cancer-specific genomic…
3 weeks ago globenewswire.com
Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
SALT LAKE CITY and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine and SOPHiA GENETICS (NASDAQ: SOPH)…
-
1 month ago benzinga.com
Craig-Hallum Maintains Buy on Myriad Genetics, Raises Price Target to $8
Craig-Hallum analyst John Wilkin maintains Myriad Genetics (NASDAQ:MYGN) with a Buy and raises the price target from $4 to $8.
-
1 month ago defenseworld.net
Applied Dna Sciences (NASDAQ:BNBX) and Myriad Genetics (NASDAQ:MYGN) Head to Head Analysis
Applied Dna Sciences (NASDAQ: BNBX - Get Free Report) and Myriad Genetics (NASDAQ: MYGN - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the…
1 month ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares moved upwards by 30.0% to $2.08 during Thursday's after-market session. The company's market cap stands at $3.2 million. cbdMD (AMEX:YCBD) stock…
-
1 month ago benzinga.com
Myriad Genetics Affirms FY2026 Sales Guidance of $770.000M-$790.000M vs $776.790M Est
Myriad Genetics (NASDAQ:MYGN) affirms FY2026 sales outlook from $770.000 million-$790.000 million to $770.000 million-$790.000 million vs $776.790 million estimate.
1 month ago globenewswire.com
Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial
SALT LAKE CITY, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Vishal Sikri has been…
1 month ago benzinga.com
Why RH Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
RH shares jumped 8.2% premarket after EPS beat estimates despite a revenue miss; Oracle and others gained, while OPTT and ZUMZ fell.
1 month ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers AEON Biopharma (AMEX:AEON) stock moved upwards by 8.9% to $0.32 during Thursday's after-market session. The company's market cap stands at $11.5 million. Picard Medical (AMEX:PMI) stock moved…
-
1 month ago benzinga.com
UBS Maintains Neutral on Myriad Genetics, Lowers Price Target to $3.6
UBS analyst Lu Li maintains Myriad Genetics (NASDAQ:MYGN) with a Neutral and lowers the price target from $6 to $3.6.
2 months ago barrons.com
This Biotech Stock Got a Rare Double-Downgrade. Its Profitability Problem Just Got Worse.
Piper Sandler cuts Myriad Genetics stock to Underweight, citing doubts about the genetic testing company's path to sustainable profitability.
2 months ago benzinga.com
Cango, Nio And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around 200 points on Tuesday. Shares of Cango Inc (NYSE:CANG) fell sharply in pre-market trading as the company posted…
2 months ago globenewswire.com
Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference
SALT LAKE CITY, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces Myriad management will present…
-
2 months ago benzinga.com
Stephens & Co. Maintains Equal-Weight on Myriad Genetics, Lowers Price Target to $3
Stephens & Co. analyst Mason Carrico maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight and lowers the price target from $5 to $3.
2 months ago businesswire.com
MYGN SHAREHOLDER ALERT: Myriad Genetics Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
NEW YORK--(BUSINESS WIRE)---- $MYGN #classactionlawsuit--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Myriad Genetics, Inc. (“Myriad Genetics” or the…
2 months ago defenseworld.net
Dimensional Fund Advisors LP Reduces Stake in Myriad Genetics, Inc. $MYGN
Dimensional Fund Advisors LP trimmed its position in shares of Myriad Genetics, Inc. (NASDAQ: MYGN) by 42.6% during the first quarter, according to the company in its most recent Form 13F filing with…
2 months ago defenseworld.net
Assenagon Asset Management S.A. Reduces Holdings in Myriad Genetics, Inc. $MYGN
Assenagon Asset Management S.A. decreased its holdings in Myriad Genetics, Inc. (NASDAQ: MYGN) by 28.7% during the undefined quarter, according to the company in its most recent disclosure with the…
2 months ago defenseworld.net
Reviewing Dyadic International (NASDAQ:DYAI) and Myriad Genetics (NASDAQ:MYGN)
Dyadic International (NASDAQ: DYAI - Get Free Report) and Myriad Genetics (NASDAQ: MYGN - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast…
2 months ago gurufocus.com
Myriad Genetics (MYGN) Securities Investigation Notice - Levi & Korsinsky
Myriad Genetics (MYGN) Securities Investigation Notice - Levi and Korsinsky PR Newswire NEW YORK, Aug. 10, 2026
2 months ago prnewswire.com
Myriad Genetics (MYGN) Securities Investigation Notice - Levi & Korsinsky
Myriad Genetics reported Q2 2026 revenue of approximately $190.7 million against consensus of roughly $206-208 million, then cut full-year revenue guidance by about $90 million at the midpoint and…
2 months ago gurufocus.com
MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law
[url="]Schall, Brown and Schwartz[/url] LLP (âSBSâ), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv
2 months ago businesswire.com
MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $MYGN--MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law.
2 months ago globenewswire.com
MYRIAD INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Myriad Genetics, Inc. on Behalf of Myriad Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Myriad (MYGN) To Contact Him Directly To Discuss Their Options
-
3 months ago benzinga.com
Wells Fargo Maintains Equal-Weight on Myriad Genetics, Lowers Price Target to $3
Wells Fargo analyst Evan Stampler maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight and lowers the price target from $5.5 to $3.
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Replimune Group (NASDAQ:REPL) stock rose 96.1% to $10.61 during Friday's regular session. SCYNEXIS (NASDAQ:SCYX) stock moved upwards by 22.54% to $4.57. The market value of their outstanding…
-
3 months ago benzinga.com
TD Cowen Maintains Hold on Myriad Genetics, Lowers Price Target to $4
TD Cowen analyst Kyle Boucher maintains Myriad Genetics (NASDAQ:MYGN) with a Hold and lowers the price target from $6 to $4.
3 months ago benzinga.com
Crude Oil Gains 1%; Apple Shares Tumble After Q3 Results
Dow up 0.38%, NASDAQ up 0.25%, S&P 500 up 0.22%. Consumer discretionary shares up 5.6%, materials stocks down 2.7%. Apple beats estimates, shares down 9%.
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Replimune Group (NASDAQ:REPL) shares increased by 134.6% to $12.69 during Friday's pre-market session. Moleculin Biotech (NASDAQ:MBRX) shares increased by 17.64% to $1.2. The market value of…
3 months ago benzinga.com
Apple, Stryker, Coinbase And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures rise, Nasdaq 100 up 300 points. Apple Inc shares fall 7.4% despite beating analyst estimates for Q3. Other stocks also dip in pre-market.
3 months ago benzinga.com
Why Amazon Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Amazon reported strong Q2 results, beating revenue and earnings estimates. Shares jumped 11.9% in pre-market trading while other stocks also saw gains/losses.
3 months ago benzinga.com
Myriad Genetics Stock Drops Sharply After Hours: What Investors Need to Know
Myriad Genetics stock fell after hours after weak Q2 results, lower guidance and an operating loss.
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Scribe Therapeutics (NASDAQ:SCTX) shares increased by 12.7% to $23.0 during Thursday's after-market session. The market value of their outstanding shares is at $297.1 million. uniQure…
-
3 months ago benzinga.com
Myriad Genetics Lowers FY2026 Sales Guidance from $860.000M-$880.000M to $770.000M-$790.000M vs $863.568M Est
Myriad Genetics (NASDAQ:MYGN) lowers FY2026 sales outlook from $860.000 million-$880.000 million to $770.000 million-$790.000 million vs $863.568 million estimate.
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Nuwellis (NASDAQ:NUWE) stock rose 40.2% to $2.65 during Wednesday's after-market session. Onconetix (NASDAQ:ONCO) shares moved upwards by 27.46% to $0.96. The company's market cap stands at…
-
4 months ago benzinga.com
Myriad Genetics Announces Expanded Availability Of Precise MRD To Patients Undergoing Treatment And Surveillance For Breast, Colorectal And Renal Cancers
Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announces expanded availability of Precise MRD™, broadening availability to patients…
-
6 months ago benzinga.com
TD Cowen Maintains Hold on Myriad Genetics, Lowers Price Target to $6
TD Cowen analyst Kyle Boucher maintains Myriad Genetics (NASDAQ:MYGN) with a Hold and lowers the price target from $7 to $6.
-
6 months ago benzinga.com
Wells Fargo Maintains Equal-Weight on Myriad Genetics, Lowers Price Target to $5.5
Wells Fargo analyst Brandon Couillard maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight and lowers the price target from $6 to $5.5.